We are live on
!
Find out more
William Blair & Company Portfolio holdings
AUM
$34.9B
1-Year Est. Return
18.88%
This Fund
S&P 500
This Quarter
Est. Return
+5.64%
1 Year Est. Return
+18.88%
3 Year Est. Return
+73.84%
5 Year Est. Return
+90.13%
10 Year Est. Return
+512.03%
AUM
$11.3B
AUM Growth
+$589M
(+5.5%)
Cap. Flow
+$20.5M
Cap. Flow
% of AUM
0.18%
Top 10 Holdings %
Top 10 Hldgs %
17.02%
Holding
1,387
New
148
Increased
486
Reduced
533
Closed
92
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fortive
FTV
|
+$47.4M |
| 2 |
AGN
Allergan plc
AGN
|
+$38.9M |
| 3 |
NVRO
NEVRO CORP.
NVRO
|
+$24.1M |
| 4 |
Netflix
NFLX
|
+$21.5M |
| 5 |
Waste Management
WM
|
+$21.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$45.3M |
| 2 |
MDVN
MEDIVATION, INC.
MDVN
|
+$33.2M |
| 3 |
Danaher
DHR
|
+$28.3M |
| 4 |
FLTX
Fleetmatics Group PLC
FLTX
|
+$25.2M |
| 5 |
Healthcare Services Group
HCSG
|
+$24.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.99% |
| 2 | Technology | 15.43% |
| 3 | Financials | 11.87% |
| 4 | Industrials | 11.27% |
| 5 | Consumer Discretionary | 10.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
iShares Core S&P US Value ETF
IUSV
$27.2B
| $11.2M | 0.1% |
243,393
-3,243
| -1% | -$149K |
|
202
IBM
IBM
$211B
| $11.2M | 0.1% |
73,865
+1,172
| +2% | +$178K |
|
203
CME Group
CME
$96.3B
| $11.2M | 0.1% |
106,968
-16,924
| -14% | -$1.77M |
|
204
Paylocity
PCTY
$7.38B
| $11.1M | 0.1% |
249,974
-29,400
| -11% | -$1.3M |
|
205
Unifirst Corp
UNF
$5.3B
| $11M | 0.1% |
83,784
-500
| -0.6% | -$61.6K |
|
|
NVO
206
Novo Nordisk
NVO
$208B
| $10.9M | 0.1% |
526,264
-20,896
| -4% | -$518K |
|
207
TJX Companies
TJX
$174B
| $10.7M | 0.09% |
287,002
+60,930
| +27% | +$2.38M |
|
|
CLR
208
DELISTED
CONTINENTAL RESOURCES INC.
CLR
| $10.6M | 0.09% |
204,848
-886
| -0.4% | -$41.2K |
|
209
Emerson Electric
EMR
$83.9B
| $10.5M | 0.09% |
193,128
+4,092
| +2% | +$219K |
|
210
Vanguard S&P 500 ETF
VOO
$979B
| $10.5M | 0.09% |
52,948
-1,161
| -2% | -$230K |
|
211
US Bancorp
USB
$98.2B
| $10.5M | 0.09% |
245,090
+6,242
| +3% | +$265K |
|
212
iShares Russell 3000 ETF
IWV
$19.6B
| $10.5M | 0.09% |
81,845
-5,463
| -6% | -$698K |
|
213
American Express
AXP
$227B
| $10.4M | 0.09% |
162,635
+1,844
| +1% | +$118K |
|
214
Bank of America
BAC
$435B
| $10.1M | 0.09% |
644,297
+13,133
| +2% | +$196K |
|
|
EXAS
215
DELISTED
Exact Sciences
EXAS
| $10.1M | 0.09% |
542,325
-17,613
| -3% | -$310K |
|
216
BioMarin Pharmaceuticals
BMRN
$11.6B
| $9.83M | 0.09% |
106,212
-4,346
| -4% | -$409K |
|
217
Ulta Beauty
ULTA
$22B
| $9.74M | 0.09% |
40,947
-3,462
| -8% | -$875K |
|
218
Plains All American Pipeline
PAA
$17.3B
| $9.73M | 0.09% |
309,792
-9,038
| -3% | -$258K |
|
219
UnitedHealth
UNH
$376B
| $9.65M | 0.09% |
68,905
+19,630
| +40% | +$2.75M |
|
220
Harley-Davidson
HOG
$2.58B
| $9.55M | 0.08% |
181,665
+281
| +0.2% | +$14.5K |
|
221
Vanguard Total International Bond ETF
BNDX
$81.9B
| $9.41M | 0.08% |
167,929
-5,199
| -3% | -$291K |
|
222
MaxLinear
MXL
$6.06B
| $9.38M | 0.08% |
462,528
-4,286
| -0.9% | -$84.2K |
|
223
Coca-Cola
KO
$377B
| $9.31M | 0.08% |
219,947
+5,914
| +3% | +$259K |
|
|
ZOES
224
DELISTED
Zoe's Kitchen, Inc.
ZOES
| $9.27M | 0.08% |
417,741
+29,463
| +8% | +$935K |
|
225
State Street Health Care Select Sector SPDR ETF
XLV
$41.9B
| $9.25M | 0.08% |
128,265
+6,963
| +6% | +$512K |
|
Similar funds
SAM
VIA
William Blair & Company's Q3 2016 Portfolio in Review
As of Q3 2016, William Blair & Company held 1,387 positions worth $11.3B, up 5.5% from $10.7B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
William Blair & Company's Q3 2016 filing shows 148 new, 486 increased, 533 reduced and 92 closed positions. Its largest new stake was Fortive: 1,476,720 shares worth $47.4M. The largest sale was Gilead Sciences, an estimated $45.3M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 20% a quarter earlier, followed by Technology and Financials.
- William Blair & Company's largest Q3 2016 buy was Fortive: 1,476,720 shares worth $47.4M.
- William Blair & Company added most to Allergan plc in Q3 2016, an estimated $38.9M increase.
- William Blair & Company's biggest Q3 2016 reduction was Gilead Sciences, cutting an estimated $45.3M.
- William Blair & Company fully exited IHS INC CL-A COM STK in Q3 2016, selling an estimated $6.24M.
- William Blair & Company's ten largest holdings make up 17% of its $11.3B portfolio in Q3 2016.
- William Blair & Company opened 148 new positions and closed 92 in Q3 2016.
- William Blair & Company's portfolio value rose 5.5% quarter-over-quarter to $11.3B.
Based on William Blair & Company's 13F filing for Q3 2016, filed 14 Nov 2016.